Vaxcyte, Inc. (PCVX) stock
PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$68.62+2.26 (+3.41%)
Close on Nov 11, 2026Market cap $10.21BP/E –Yield 0.00%
Vaxcyte EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Vaxcyte's EPS for the twelve months ending Sep 30, 2026 was -$8.07. For fiscal 2025 it was -$5.63. The highest annual figure on record is -$1.93 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$5.63 | – |
| FY2024 | Dec 31, 2024 | -$3.80 | – |
| FY2023 | Dec 31, 2023 | -$4.14 | – |
| FY2022 | Dec 31, 2022 | -$3.44 | – |
| FY2021 | Dec 31, 2021 | -$1.93 | – |
| FY2020 | Dec 31, 2020 | -$3.02 | – |
| FY2019 | Dec 31, 2019 | -$13.25 | – |
| FY2018 | Dec 31, 2018 | -$8.12 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.99 | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.97 | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.30 | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.81 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.56 | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.22 | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.04 | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.01 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.83 | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.10 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.85 | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.76 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.91 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.70 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.70 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.99 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.93 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.80 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.68 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.54 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.51 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.46 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.41 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.41 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.41 | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.72 | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.70 | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.69 | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.93 | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.90 | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.72 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?